Areas of Practice
Firm Management Positions
White Collar and Government Enforcement, Chair
Honors and Awards
- Named one of "America's Leading Lawyers in White Collar Crime & Government Investigations" by Chambers USA, 2013
- Selected for inclusion in Pennsylvania Super Lawyers, 2007 to present
- Director's Award for Outstanding Performance, U.S. Department of Justice
- Prosecutor of the Year Award, International Association of Financial Crimes Investigators
- AV Peer Review Rated, Martindale-Hubbell
Memberships and Affiliations
Co-Chair, ABA Qui Tam Substantive Committee, Criminal Justice Section’s White Collar Crime Committee
Past Co-Chair, ABA Criminal Law Section, Sub-Committee for White Collar Crime, Mid-Atlantic Region
Vice President, Federal Bar Association of Philadelphia, Criminal Law Committee
Vice Chair, White Collar Crime Committee, National Association of Criminal Defense Lawyers
J.D., Georgetown University Law Center, 1985
- Editor, The American Criminal Law Review
B.A., Amherst College, 1981, cum laude
- New Jersey
- New York
- Honorable James S. Holden, U.S. District Court for the District of Vermont
Christopher R. Hall
As a former federal prosecutor, Christopher Hall represents corporations and individuals facing allegations of wrongful conduct. He assists clients during internal investigations, government criminal investigations, government civil enforcement actions, and related civil proceedings such as False Claims Act and securities fraud proceedings. Chris places particular emphasis on the healthcare, financial service, defense, and government contract industries. His subject matter experience within these industries includes wire/mail fraud, healthcare fraud and abuse, false claims, antitrust, securities fraud, environmental crimes, tax crimes, bank fraud, government contract fraud, export law violations, and public corruption. He has tried more than 30 cases to verdict in federal courts.
Chris has brought to trial tax evasion and money laundering prosecutions and spearheaded dozens of complex, multi-federal agency investigations. He also led the Justice Department’s investigation into the collapse of the Allegheny Health System, at the time the state's largest employer. In that matter, Chris spent two years immersed in issues of corporate accounting, manipulation of earnings through financial reporting, techniques for smoothing earnings, reserve setting, and the alleged misuse of charitable funds.
He also has experience with multi-agency, parallel criminal and civil investigations, including the off-label marketing of pharmaceutical drugs in violation of FDA statutes and regulations, and schemes to defraud Federal healthcare programs and private insurers through the submission of false and inflated claims for reimbursement and payment. Chris has a thorough and current understanding of the workings of the FDA, the HHS OIG, the Antitrust, Criminal, and Civil Divisions of the Department of Justice, the SEC, the IRS, HUD, EPA, and the Departments of Defense, Homeland Security, and Labor.
In situations that warrant prompt and professional resolutions with the United States, Chris’s past negotiation of settlements on behalf of the federal government give him intimate familiarity with the complexities at hand and how best to proceed. He also has experience with crafting, implementing, and auditing industry-specific compliance programs that incorporate guidance provided by pertinent regulatory bodies, industry-adopted best practices and the U.S. Sentencing Guidelines.
Finally, Chris speaks Spanish fluently. He has traveled to South America for the Department of Justice to help the Bolivian government draft money laundering legislation. He has also conducted investigations in Spanish, and has explained the nuances of federal criminal law in that language.
- Represented three employees of a medical device manufacturer who had been targeted for indictment under the Food, Drug and Cosmetic Act; persuaded the U.S. Department of Justice (DOJ) to reverse decision to charge.
- Represented a financial advisory company and its president in a long-running (and continuing) probe of the public finance markets by the Antitrust Division of the DOJ and the Securities and Exchange Commission.
- Represented a senior official of a large government agency during a federal investigation of sexual and other misconduct by the agency's Executive Director and related civil litigation. A dismissal of two civil class actions filed against his client and several other senior agency officials was obtained.
- Represented a healthcare provider alleged to have reused single-use medical devices during surgical procedures creating a risk of infection; conducted an emergency internal assessment, counseled the client on remedial and disciplinary steps, and assisted the client in a self disclosure to the State Medical Licensing Board.
- Represented a federal grant recipient accused of misusing public funds obtaining a reversal of an order that had suspended the grantee from the federal grant program.
- Assessed the sales and promotional practices of a global pharmaceutical company in response to a complaint by a former employee and helped the client design a remedial action plan. No federal investigation or whistleblower action has ensued to date.
- Represented an alleged “robo-signer” of mortgages in connection with a DOJ investigation and related civil class actions concerning lending practices by the nation’s largest banks and mortgage lending companies. The federal government has exercised its discretion not to proceed against the client. State and civil class actions continue.
- Assessed the effectiveness of the compliance program and policies of a nationally recognized health system.
- Represented a senior executive of a failed commodities broker in connection with a DOJ investigation, resulting in no criminal charges.
- Represented a board member of a global medical device manufacturer in connection with a DOJ off-label marketing probe, resulting in no charges or disbarment of the board member.
- Conducted an internal investigation of a debtor-in-possession to assess fraud and kickback allegations
- Represented several current and former employees of a global pharmaceutical company in connection with a DOJ off-label marketing probe.
- Represented an employee of a global medical device manufacturer in connection with a DOJ investigation of off-label promotion allegations, resulting in no charges.
- Conducted a three-month internal investigation into an alleged false/improperly supported Contract Disputes Act (CDA) claim against the Navy by a publicly traded government contractor, on behalf of the Audit Committee of the company's Board of Directors.
In his role as an Assistant U.S. Attorney, Chris prosecuted a number of significant, complex matters including:
- A government contracts fraud case in which a supplier to the United States admitted that it had misrepresented expenses in a cost-plus contract through a rebate scheme.
- One of the first criminal healthcare cases brought to trial in the Eastern District of Pennsylvania, for which he received the Director's Award from the Department of Justice for outstanding performance.
- The conviction of a Department of Defense supplier on charges that it intentionally deceived and failed to pay subcontractors.
- Several environmental criminal cases involving illegal disposal activities. These trials included the first environmental justice prosecution in the Eastern District of Pennsylvania, which resulted in a guilty plea by an international conglomerate and a $1 million clean up of an under-served neighborhood in southwest Philadelphia.
- A case involving illegal shipments of products to Iran in violation of the President's embargo.
- The first predatory lending case brought to trial in the Eastern District of Pennsylvania.
- Cases involving the theft of funds from a major local University and a major local hospital system.
- A public corruption matter arising from the theft of monies from a program funded by the Department of Housing and Urban Development.
- The conviction of a former, disgruntled employee under the Computer Fraud and Abuse Act for compromising a company's firewalls and exposing proprietary information and confidential personal data to internet hackers.
News & Press Releases
- September 25, 2013
- June 11, 2013
- May 22, 2013
- Three Philadelphia Lawyers To Serve As Co-Chairs of ABA White Collar Crime Qui Tam Substantive CommitteeSeptember 24, 2012
- June 15, 2012
- December 2, 2011
- November 23, 2010
- June 8, 2010
- February 15, 2010
- May 21, 2009
- May 20, 2008
- September 26, 2006
Articles, Alerts & Newsletters
- November 2013
- November 2013
- Google’s scanning of emails may constitute wiretapping: Federal District Court denies Google’s motion to dismiss class action lawsuitOctober 2013
- Health care executives should heed recent trend of significant prison sentences for Medicare fraud convictionsSeptember 2013
- “Love and Marriage” – New Jersey Supreme Court Poised to Determine Whether the Marital Privilege Can Defeat Wiretap EvidenceAugust 2013
- July 2013
- Increased cGMP Enforcement has Gone International: South Korean Action Against Johnson & Johnson Serves as WarningJune 2013
- May 2013
- Second Highest Penalty in FCPA History Comes with a Caution from the Bench about the Limits of the Act’s JurisdictionMay 2013
- April 2013
- Casting a Smaller Net: Seventh Circuit Requires "Net Trebling" Under FCA – Potentially Impacting Settlement Dynamics for all Industries Subject to Government EnforcementApril 2013
- Supreme Court Holds SEC to Five-Year Statute of Limitations for Civil Enforcement Actions; Decision May Extend to Other Federal AgenciesMarch 2013
- The D.C. Circuit Expands the Scope of Honest-Services Fraud and Illegal-Gratuities Prosecutions in Ring v. United StatesMarch 2013
- March 2013
- Death and Taxes? Recent Supreme Court Arguments in Gabelli v. SEC Concerning a General Statute of Limitations for Civil Fines May Also Affect How Long the IRS Has to Assess PenaltiesJanuary 2013
- The SEC’s Annual Report on the Dodd-Frank Whistleblower Program: Statistics Suggest Best Practices for an Effective Compliance and Ethics ProgramDecember 2012
- December 2012
- November 2012
- November 1, 2012
- October 19, 2012Health Lawyers Weekly
- The Champion
- Companies that Source Pharmaceutical and Food Ingredients in the People’s Republic of China Should Take Heed of the Government’s Response to Recent Chromium ContaminationAugust 2012
- D.C. Circuit Affirms Exclusion from Federal Health Care Programs Under “Responsible Corporate Officer” Doctrine — with a TwistAugust 2012
- July 2012
- Does “Hidden” ESI Meet the Government’s Burden of Producing Evidence in “Reasonably Usable” Form? Or Is It Pie-in-the-Skype?July 2012
- June 2012
- The D.C. Circuit Empowers Relators in Qui Tam Actions in United States ex rel. Schweizer v. Océ N.V.May 2012
- April 2012
- Delaware Chancery Court Finds No Inherent Conflict Between Strict Criminal Liability Under the Responsible Corporate Officer Doctrine and Indemnification for Legal Fees and ExpensesMarch 2012
- SEC Employee and Public Interest Group Prompt Enforcement Division to Reform Document Retention PracticesFebruary 2012
- February 2012
- January 2012
- November 2011
- Federal Government Urges Appellate Court to Uphold Executives' Exclusions from Federal Health Care ProgramsOctober 2011
- September 2011
- September 2011
- August 2011
- Recent Third Circuit Decision Limits False Claims Act Liability to False Representations Made under Laws that Condition Payment of Government FundsJuly 2011
- Purdue Executives Ask Appellate Court to Overturn Their Exclusions from Federal Health Care ProgramsJuly 2011
- June 2011
- June 2011
- Issues Confronting Responsible Corporate Officers in the New Era of Government Food & Drug EnforcementWhite Collar Crime Committee Newsletter
- March 2011
- February 2011
- February 2011
- 2011Food Drug Law Journal
- D.C. district court affirms HHS-OIG's exclusion of executives convicted under the Responsible Corporate Officer DoctrineDecember 2010
- The Champion
- January 2009
- January 2009
- May 2007
- March 6, 2007The Legal Intelligencer
- High Court Strictly Applies "Original Source" Requirement To Preclude A Qui Tam Relator's False Claims Act AwardMarch 2007
- March 2007The Metropolitan Corporate Counsel
- 2007Food and Drug Law Journal, Volume 62 Number 2
- September 2006
Tools & Books
- December 14, 2012
- November 2012
- March 21, 2011
- Comments on Proposed Rules for Implementing the Whistleblower Provisions of Section 21F of the Securities Exchange Act of 1934December 17, 2010
- March 1, 2010
- June 7, 2007